"Chemoradiotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatment that combines chemotherapy with radiotherapy.
| Descriptor ID |
D059248
|
| MeSH Number(s) |
E02.186.079 E02.319.164 E02.815.160
|
| Concept/Terms |
Chemoradiotherapy- Chemoradiotherapy
- Chemoradiotherapies
- Radiochemotherapy
- Radiochemotherapies
Concurrent Chemoradiotherapy- Concurrent Chemoradiotherapy
- Chemoradiotherapies, Concurrent
- Chemoradiotherapy, Concurrent
- Concurrent Chemoradiotherapies
- Synchronous Chemoradiotherapy
- Chemoradiotherapies, Synchronous
- Chemoradiotherapy, Synchronous
- Synchronous Chemoradiotherapies
- Concurrent Radiochemotherapy
- Concurrent Radiochemotherapies
- Radiochemotherapies, Concurrent
- Radiochemotherapy, Concurrent
- Concomitant Chemoradiotherapy
- Chemoradiotherapies, Concomitant
- Chemoradiotherapy, Concomitant
- Concomitant Chemoradiotherapies
- Concomitant Radiochemotherapy
- Concomitant Radiochemotherapies
- Radiochemotherapies, Concomitant
- Radiochemotherapy, Concomitant
|
Below are MeSH descriptors whose meaning is more general than "Chemoradiotherapy".
Below are MeSH descriptors whose meaning is more specific than "Chemoradiotherapy".
This graph shows the total number of publications written about "Chemoradiotherapy" by people in this website by year, and whether "Chemoradiotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 4 | 6 |
| 2017 | 24 | 24 | 48 |
| 2018 | 22 | 24 | 46 |
| 2019 | 11 | 4 | 15 |
| 2020 | 1 | 3 | 4 |
| 2021 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Chemoradiotherapy" by people in Profiles.
-
The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic. JAMA Oncol. 2021 05 01; 7(5):675-676.
-
Impact of COVID-19 on treatment modalities and short-term outcomes of rectal cancer following neoadjuvant chemoradiotherapy: a retrospective study. Br J Surg. 2021 Apr 30; 108(4):e164-e165.
-
Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis. Cancer Invest. 2021 Apr; 39(4):315-320.
-
Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic. Gynecol Oncol. 2021 05; 161(2):414-421.
-
Management of prostate cancer radiotherapy during the COVID-19 pandemic: A necessary paradigm change. Cancer Treat Res Commun. 2021; 27:100331.
-
Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial. Oral Oncol. 2021 02; 113:105112.
-
Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave. Crit Rev Oncol Hematol. 2021 Jan; 157:103189.
-
Breast, Prostate, and Rectal Cancer: Should 5-5-5 Be a New Standard of Care? Int J Radiat Oncol Biol Phys. 2020 10 01; 108(2):390-393.
-
Use of Immunotherapy in Patients With Cancer During the COVID-19 Pandemic. Oncology (Williston Park). 2020 09 15; 34(9):370-376.
-
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era. ESMO Open. 2020 09; 5(5):e000885.